- Nelson Advisors LLP
- About Us
- Contact Us
- Message Us
- Meet Us
- FAQ's
- Mission and Vision
- Expertise
- Services
- Lower to Mid Market
- Corporate Divestitures
- Healthcare AI
- Digital Health
- Transactions
- Behaviour Change
- App Platform Data AI
- Research
- University Business Schools
- Thought Leadership
- Careers
- Lloyd G Price
- Press and Awards
- Blog
- Insights
- Newsletter
Nelson Advisors referenced by Astra Capital Research
NA
Nelson Advisors referenced by Astra Capital Research
Astra Capital is a private equity and asset management firm investing in lower mid-market, privately owned businesses across Australia, New Zealand and Southeast Asia. We work with founders, operators and management teams building enduring businesses in healthcare, wellness and beauty, consumer, and specialty retail. Our approach is disciplined and operator-led, focused on partnering with businesses for the long term rather than simply seeking an exit.
Astra Capital partners with founders, operators and management teams building enduring businesses across healthcare, wellness and beauty, consumer, and specialty retail in Australia, New Zealand and Southeast Asia. If you are building or leading a business in one of these sectors and would like to discuss capital, strategy, or an eventual transaction, we would welcome the conversation.
Is Cochlear a Reset Opportunity or a Structural Slowdown?
A single delayed contract renewal wiped out three quarters of Cochlear's market value. What that says about the hearing implant category, and what would need to be true for the reset to be an opportunity rather than a warning.
Astra Capital Research August 2026
Executive Summary
Cochlear Limited (ASX: COH) enters the second half of 2026 having delivered one of the more dramatic single-year re-ratings in ASX healthcare history. Shares that peaked above $350 in July 2024 traded as low as $88.74 in April 2026, a fall of roughly 75 per cent, on the back of a delayed contract renewal process for the new Nucleus Nexa implant system and a guidance cut that trimmed the midpoint of underlying profit expectations by close to 30 per cent. On 18 August 2026, Cochlear released full year results that landed at the top of its revised guidance range, with underlying net profit of $322 million, accelerating second half revenue growth of 6 per cent, and free cash flow more than doubling. The market responded by pushing shares up 7.2 per cent on the day.
This paper asks whether that year of shocks amounts to a genuine reset and a mispriced entry point into a structurally growing category where Cochlear holds roughly half of global market share, or whether it is the first visible sign of a maturing franchise meeting a structurally repricing channel, most visibly China's volume based procurement program, alongside consolidation among global peers. We hold a position in Cochlear. This paper sets out that disclosure, the bull and bear cases in full, and a practical framework for judging the company's next results and AGM on their merits rather than on narrative alone.
References
Cochlear Limited, FY26 Full Year Results and ASX announcement, 18 August 2026. cochlear.com
Cochlear Limited, HY26 Half Year Result, ASX and media release, 13 February 2026. investsmart.com.au
Cochlear Limited, Trading update and reduction to FY26 earnings guidance, ASX announcement, 22 April 2026. announcements.asx.com.au
Cochlear Limited, Notice of 2026 Annual General Meeting key dates, 26 October 2026. tipranks.com
IG International, Cochlear FY26 earnings preview, 12 August 2026. ig.com
Investing.com, Cochlear FY26 slides: cash flow doubles despite margin pressure, 18 August 2026. investing.com
Healthcare Digital, Australian HealthTech Market: 2026 State of Play and Outlook to 2028. healthcare.digital